Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141041456> ?p ?o ?g. }
- W2141041456 endingPage "275" @default.
- W2141041456 startingPage "268" @default.
- W2141041456 abstract "No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, rifampicin inhibited formation of α-synuclein fibrils, the neuropathological hallmark of the disease. We aimed to assess the safety and efficacy of rifampicin in patients with multiple system atrophy.In this randomised, double-blind, placebo-controlled trial we recruited participants aged 30-80 years with possible or probable multiple system atrophy from ten US medical centres. Eligible participants were randomly assigned (1:1) via computer-generated permuted block randomisation to rifampicin 300 mg twice daily or matching placebo (50 mg riboflavin capsules), stratified by subtype (parkinsonian vs cerebellar), with a block size of four. The primary outcome was rate of change (slope analysis) from baseline to 12 months in Unified Multiple System Atrophy Rating Scale (UMSARS) I score, analysed in all participants with at least one post-baseline measurement. This study is registered with ClinicalTrials.gov, number NCT01287221.Between April 22, 2011, and April 19, 2012, we randomly assigned 100 participants (50 to rifampicin and 50 to placebo). Four participants in the rifampicin group and five in the placebo group withdrew from study prematurely. Results of the preplanned interim analysis (n=15 in each group) of the primary endpoint showed that futility criteria had been met, and the trial was stopped (the mean rate of change [slope analysis] of UMSARS I score was 0.62 points [SD 0.85] per month in the rifampicin group vs 0.47 points [0.48] per month in the placebo group; futility p=0.032; efficacy p=0.76). At the time of study termination, 49 participants in the rifampicin group and 50 in the placebo group had follow-up data and were included in the final analysis. The primary endpoint was 0.5 points (SD 0.7) per month for rifampicin and 0.5 points (0.5) per month for placebo (difference 0.0, 95% CI -0.24 to 0.24; p=0.82). Three (6%) of 50 participants in the rifampicin group and 12 (24%) of 50 in the placebo group had one or more serious adverse events; none was thought to be related to treatment.Our results show that rifampicin does not slow or halt progression of multiple system atrophy. Despite the negative result, the trial does provide information that could be useful in the design of future studies assessing potential disease modifying therapies in patients with multiple system atrophy.National Institutes of Health, Mayo Clinic Center for Translational Science Activities, and Mayo Funds." @default.
- W2141041456 created "2016-06-24" @default.
- W2141041456 creator A5003255743 @default.
- W2141041456 creator A5007240138 @default.
- W2141041456 creator A5009268783 @default.
- W2141041456 creator A5026885325 @default.
- W2141041456 creator A5031449295 @default.
- W2141041456 creator A5032394611 @default.
- W2141041456 creator A5039483634 @default.
- W2141041456 creator A5047373167 @default.
- W2141041456 creator A5060200677 @default.
- W2141041456 creator A5066232154 @default.
- W2141041456 creator A5073930337 @default.
- W2141041456 creator A5074107549 @default.
- W2141041456 creator A5080057970 @default.
- W2141041456 creator A5082064376 @default.
- W2141041456 creator A5086023917 @default.
- W2141041456 creator A5091346458 @default.
- W2141041456 date "2014-03-01" @default.
- W2141041456 modified "2023-10-12" @default.
- W2141041456 title "Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial" @default.
- W2141041456 cites W1492178107 @default.
- W2141041456 cites W1566264161 @default.
- W2141041456 cites W1588992473 @default.
- W2141041456 cites W1952583315 @default.
- W2141041456 cites W1964996062 @default.
- W2141041456 cites W1979323586 @default.
- W2141041456 cites W1979591162 @default.
- W2141041456 cites W1982852824 @default.
- W2141041456 cites W1985988430 @default.
- W2141041456 cites W1986045469 @default.
- W2141041456 cites W1989305371 @default.
- W2141041456 cites W1991087865 @default.
- W2141041456 cites W1991849900 @default.
- W2141041456 cites W2002388265 @default.
- W2141041456 cites W2012985649 @default.
- W2141041456 cites W2024314367 @default.
- W2141041456 cites W2027679622 @default.
- W2141041456 cites W2028803408 @default.
- W2141041456 cites W2039753388 @default.
- W2141041456 cites W2040566836 @default.
- W2141041456 cites W2044841974 @default.
- W2141041456 cites W2051306971 @default.
- W2141041456 cites W2062032504 @default.
- W2141041456 cites W2073392849 @default.
- W2141041456 cites W2086887131 @default.
- W2141041456 cites W2100592729 @default.
- W2141041456 cites W2106573601 @default.
- W2141041456 cites W2111486424 @default.
- W2141041456 cites W2112499943 @default.
- W2141041456 cites W2114317747 @default.
- W2141041456 cites W2114832183 @default.
- W2141041456 cites W2118775107 @default.
- W2141041456 cites W2122211082 @default.
- W2141041456 cites W2123385434 @default.
- W2141041456 cites W2143755946 @default.
- W2141041456 cites W2153026275 @default.
- W2141041456 cites W2153235303 @default.
- W2141041456 cites W2155299862 @default.
- W2141041456 doi "https://doi.org/10.1016/s1474-4422(13)70301-6" @default.
- W2141041456 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4030757" @default.
- W2141041456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24507091" @default.
- W2141041456 hasPublicationYear "2014" @default.
- W2141041456 type Work @default.
- W2141041456 sameAs 2141041456 @default.
- W2141041456 citedByCount "89" @default.
- W2141041456 countsByYear W21410414562014 @default.
- W2141041456 countsByYear W21410414562015 @default.
- W2141041456 countsByYear W21410414562016 @default.
- W2141041456 countsByYear W21410414562017 @default.
- W2141041456 countsByYear W21410414562018 @default.
- W2141041456 countsByYear W21410414562019 @default.
- W2141041456 countsByYear W21410414562020 @default.
- W2141041456 countsByYear W21410414562021 @default.
- W2141041456 countsByYear W21410414562022 @default.
- W2141041456 countsByYear W21410414562023 @default.
- W2141041456 crossrefType "journal-article" @default.
- W2141041456 hasAuthorship W2141041456A5003255743 @default.
- W2141041456 hasAuthorship W2141041456A5007240138 @default.
- W2141041456 hasAuthorship W2141041456A5009268783 @default.
- W2141041456 hasAuthorship W2141041456A5026885325 @default.
- W2141041456 hasAuthorship W2141041456A5031449295 @default.
- W2141041456 hasAuthorship W2141041456A5032394611 @default.
- W2141041456 hasAuthorship W2141041456A5039483634 @default.
- W2141041456 hasAuthorship W2141041456A5047373167 @default.
- W2141041456 hasAuthorship W2141041456A5060200677 @default.
- W2141041456 hasAuthorship W2141041456A5066232154 @default.
- W2141041456 hasAuthorship W2141041456A5073930337 @default.
- W2141041456 hasAuthorship W2141041456A5074107549 @default.
- W2141041456 hasAuthorship W2141041456A5080057970 @default.
- W2141041456 hasAuthorship W2141041456A5082064376 @default.
- W2141041456 hasAuthorship W2141041456A5086023917 @default.
- W2141041456 hasAuthorship W2141041456A5091346458 @default.
- W2141041456 hasBestOaLocation W21410414562 @default.
- W2141041456 hasConcept C126322002 @default.
- W2141041456 hasConcept C141071460 @default.
- W2141041456 hasConcept C142724271 @default.
- W2141041456 hasConcept C168563851 @default.